Indeed, in the first sample (left), more than 70% of cells are neoplastic, but only a subset of them (23% of the alleles) harbors the EGFR L858R mutation; conversely, in the second ADC (right), the percentage of mutated allele (49%) indicates that about all tumor cells in the sample (tumor content >70%) have the KRAS G12D mutation. The gene discussed is KRAS; the disease is neoplasm.